Introduction MRD monitoring is recommended for treatment response evaluation in clinical AML trials (ELN-2022 guidelines: Heuser et al, PMID 34724563). Besides molecular biology methods, multiparametric flow cytometry represents the most reliable approach. In this...
IntroductionMeasurable residual disease (MRD) assessment has become a crucial prognostic tool in patients diagnosed with acute myeloid leukemia (AML) undergoing intensive chemotherapy. While its prognostic impact is well-documented in these patients, its value among...
IntroductionALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy) is a multi-arm platform trial designed to obtain proof-of-concept for novel therapies targeting measurable residual disease (MRD) or...
Background: Several small studies have suggested improved outcomes by adding a FLT3 inhibitor (FLT3i) to hypomethylating agent (HMA)/venetoclax in older patients (pts) with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). In this large, pooled analysis of...
BackgroundFor fit patients (pts), combining kinase inhibitors (midostaurin, quizartinib) with intensive chemotherapy is standard of care for FLT3mutated AML. New studies also suggest a role for kinase inhibitors (e.g. quizartinib) in modifying disease history in pts...
Background: The menin inhibitor revumenib (previously SNDX-5613), is a potent, oral, selective inhibitor of the menin–KMT2A interaction which is a dependency in acute leukemia caused by either rearrangement of the KMT2A (KMT2Ar) or Nucleoporin 98 (NUP98r) genes, or...
Recent Comments